Company Description
Oncotelic Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing drugs for the treatment of orphan oncology indications.
The company's lead product candidate is OT-101, an antisense against TGF-ß2, which is in phase 3 clinical trials for pancreatic cancer and glioblastoma, as well as develops OT-101 for the treatment of various viruses, including severe acute respiratory syndrome and coronavirus.
It also develops OXi4503 for the treatment of acute myeloid leukemia and myelodysplastic syndromes; and CA4P for the treatment of advanced metastatic melanoma; intranasal drug and delivery system for intra-nasal Apomorphine for the treatment of Parkinson's Disease, erectile disfunction, and female sexual disfunction; Artemisinin, a natural derivative from an Asian herb Artemisia Annua; and AI based technologies to enhance the development and commercialization of Artemisinin based products and support technologies.
Oncotelic Therapeutics, Inc. is based in Agoura Hills, California.
Country | Canada |
IPO Date | Aug 26, 1993 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 22 |
CEO | Dr. Vuong Trieu Ph.D. |
Contact Details
Address: 29397 Agoura Rd., #107 Aguora Hills, California 91301 United States | |
Phone | 650-635-7000 |
Website | oncotelic.com |
Stock Details
Ticker Symbol | OTLC |
Exchange | OTCMKTS |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0000908259 |
CUSIP Number | 628341109 |
ISIN Number | US6283411097 |
Employer ID | 13-3679168 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Vuong Trieu Ph.D. | Chairman and Chief Executive Officer |
Amit Shah | Chief Financial Officer |
Dr. Anthony E. Maida III, B.A., MA, MBA, Ph.D. | Chief Clinical Officer of Translational Medicine and Director |
Saranjit Saund | CBO and GM of AI Division |
Steven W. King | Consultant and Director |
Dr. Larn Hwang | Chief Scientific Officer |
Dr. Seymour Howard Fein M.D. | Chief Medical Officer |
Burcak Beser | Chief Technology Officer of AI Division |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Apr 22, 2024 | EFFECT | Notice of Effectiveness |
Apr 18, 2024 | POS AM | Post-Effective amendments for registration statement |
Apr 12, 2024 | POS AM | Post-Effective amendments for registration statement |
Apr 12, 2024 | 10-K | Annual Report |
Apr 1, 2024 | NT 10-K | Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 |
Feb 2, 2024 | 8-K | Current Report |
Nov 14, 2023 | 10-Q | Quarterly Report |
Oct 30, 2023 | 8-K | Current Report |
Aug 23, 2023 | 8-K | Current Report |
Aug 18, 2023 | 10-Q | Quarterly Report |